Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.

Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK.

Curr Pharm Des. 2012;18(32):4966-79. Review.

PMID:
22716148
2.

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL.

Neuropsychopharmacology. 2016 Jul;41(8):1974-82. doi: 10.1038/npp.2015.367. Epub 2015 Dec 28.

3.
4.

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.

Stott CG, White L, Wright S, Wilbraham D, Guy GW.

Eur J Clin Pharmacol. 2013 Apr;69(4):825-34. doi: 10.1007/s00228-012-1393-4. Epub 2012 Oct 4.

PMID:
23052407
5.

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV.

Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5.

6.

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK.

Neuropsychopharmacology. 2010 Feb;35(3):764-74. doi: 10.1038/npp.2009.184. Epub 2009 Nov 18.

7.

Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.

Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A.

J Control Release. 2017 Nov 28;266:1-7. doi: 10.1016/j.jconrel.2017.09.011. Epub 2017 Sep 8.

PMID:
28890215
8.

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S.

J Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4. Epub 2012 Nov 21.

PMID:
23180178
9.

Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z, Zuardi AW, McGuire PK.

Arch Gen Psychiatry. 2009 Jan;66(1):95-105. doi: 10.1001/archgenpsychiatry.2008.519.

PMID:
19124693
10.

Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM.

Eur Arch Psychiatry Clin Neurosci. 2009 Aug;259(5):284-92. doi: 10.1007/s00406-009-0868-5. Epub 2009 Feb 17.

PMID:
19224107
11.

Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.

Eichler M, Spinedi L, Unfer-Grauwiler S, Bodmer M, Surber C, Luedi M, Drewe J.

Planta Med. 2012 May;78(7):686-91. doi: 10.1055/s-0031-1298334. Epub 2012 Mar 12.

PMID:
22411724
12.

Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study.

Winton-Brown TT, Allen P, Bhattacharyya S, Borgwardt SJ, Fusar-Poli P, Crippa JA, Seal ML, Martin-Santos R, Ffytche D, Zuardi AW, Atakan Z, McGuire PK.

Neuropsychopharmacology. 2011 Jun;36(7):1340-8. doi: 10.1038/npp.2011.17. Epub 2011 Mar 16. Erratum in: Neuropsychopharmacology. 2011 Jul;36(8):1778. Bhattacharrya, Sagnik [corrected to Bhattacharyya, Sagnik].

13.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J.

Clin Rehabil. 2003 Feb;17(1):21-9.

PMID:
12617376
14.

Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.

Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA.

Clin Chem. 2011 Jan;57(1):66-75. doi: 10.1373/clinchem.2010.152439. Epub 2010 Nov 15.

15.

Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

Lee D, Karschner EL, Milman G, Barnes AJ, Goodwin RS, Huestis MA.

Drug Alcohol Depend. 2013 Jun 1;130(1-3):68-76. doi: 10.1016/j.drugalcdep.2012.10.011. Epub 2012 Nov 10.

16.

Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.

Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F.

J Anal Toxicol. 2005 Nov-Dec;29(8):782-9.

PMID:
16356335
17.

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.

Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S.

J Psychopharmacol. 2013 Jan;27(1):19-27. doi: 10.1177/0269881112460109. Epub 2012 Oct 5.

PMID:
23042808
18.

Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL.

Drug Alcohol Depend. 2008 Apr 1;94(1-3):191-8. doi: 10.1016/j.drugalcdep.2007.11.017.

19.

Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS.

Psychopharmacology (Berl). 2011 Nov;218(2):443-57. doi: 10.1007/s00213-011-2342-0. Epub 2011 Jun 11.

PMID:
21667074
20.

The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.

Cherniakov I, Izgelov D, Domb AJ, Hoffman A.

Eur J Pharm Sci. 2017 Nov 15;109:21-30. doi: 10.1016/j.ejps.2017.07.003. Epub 2017 Jul 20.

PMID:
28736128

Supplemental Content

Support Center